• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Doug Kass
    • Bruce Kamich
    • Jim Cramer
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks
  1. Home
  2. / Investing

BioMarin Can Trade Sideways in the Near-Term, Use It as a Buying Opportunity

Let's visit with the charts to see if things are still on track.
By BRUCE KAMICH
Nov 15, 2019 | 09:00 AM EST
Stocks quotes in this article: BMRN

In his second "Executive Decision" segment of Mad Money Thursday night, Jim Cramer sat down with Jean-Jacques Bienaime, chairman and CEO of BioMarin Pharmaceuticals (BMRN) , the orphan drug maker that's seen its shares plunge from highs of $100 down to lows near $63 as biotechs have fallen out of favor on Wall Street.

BioMarin updated investors at their annual investor conference, and Bienaime said they expect continued annual growth of 15%, just as they have for the past few years. He said their drug pipeline continues to be strong.

BioMarin's seven products are on track to deliver $2 billion in revenues, Bienaime added, and they expect to file for FDA approval for their next drug before the end of 2019.

Cramer said shares of BioMarin are incredibly cheap and he would be a buyer at these depressed levels. We looked at BMRN earlier this week where we concluded that, "BMRN has been going straight up since early October and I think the odds favor further gains with a Point and Figure target of $95." 

In this daily bar chart of BMRN, below, we can still see that things have continued to strengthen. Prices are still above the 50-day moving average line and because it is a "moving" average the older numbers are dropping off and the slope of the average line is about to go positive.

The daily On-Balance-Volume (OBV) line remains pointed up telling us that buyers of BMRN are being more aggressive. I think this is interesting behavior by buyers who could just wait and let prices come to them after the decline we have seen over the past year.

The Moving Average Convergence Divergence (MACD) oscillator is still above the zero line but some narrowing of the indicator can be seen.

In this weekly bar chart of BMRN, below, we can see little change since our last review but we can reiterate that is appears that it looks like prices are making an important reversal in the fourth quarter.

If I was writing a story on which stocks could make surprise rallies in 2020, BMRN would be on the list.

In this Pointed and Figure chart of BMRN, below, we can see that a trade at $75.96 will refresh the uptrend. Not much to ask for today or in the next few days.

Bottom line strategy: Use sideways price action in BMRN to build a long position.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

Employees of TheStreet are prohibited from trading individual securities.

TAGS: Investing | Stocks | Technical Analysis | Trading | Biotechnology | Pharmaceuticals | Mad Money | Executive Interview

More from Investing

We Are Cutting Our Market Outlook

Guy Ortmann
Mar 3, 2021 10:29 AM EST

Fewer stocks are participating in bounces from the recent increases in volatility.

Hits and Misses From the Early Days of What Would Become the Pandemic

Jonathan Heller
Mar 3, 2021 10:00 AM EST

Booking a cruise a year ago wasn't a great idea, but buying a discounted small-cap fund was; so was buying physical silver.

Canopy Growth Has Corrected but Needs More Accumulation

Bruce Kamich
Mar 3, 2021 9:46 AM EST

Let's review the charts and indicators.

XL Fleet's Charts Show Potential for a Future Purchase

Bruce Kamich
Mar 3, 2021 8:49 AM EST

A new base pattern needs to develop before taking a long position.

Hopping on a Couple Compelling Opportunities in a Market That Isn't

Bret Jensen
Mar 3, 2021 8:30 AM EST

Dips in the shares of Redhill Biopharma and FibroGen Inc. provided the chance for the author to employ his covered call strategy.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 08:50 AM EST PAUL PRICE

    Michaels: Close to a Deal?

    It appears that a deal could be announced soon. ...
  • 08:34 AM EST GARY BERMAN

    Wednesday Morning Fibocall for 3/3/2021

    SPX (Long-Term View) The 20 DMA @ 3889 with the ...
  • 06:05 PM EST PAUL PRICE

    Michael's (MIK) Up on Takeover Rumors

    The NYT says talks are underway regarding a buyout...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2021 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login